Artemis Medicare ServicesBOM:542919 -1.41%89 EBITDA Margin % is 21.27% as of Mar. 2026, which is 69% above its 10-year median of 12.55. GuruFocus rates BOM:542919 with a GF Score™ of 89/100 and a GF Value™ of ₹265.43 (Fairly Valued). The stock has 4 warning signs investors should review. Among 664 Healthcare Providers & Services companies, Artemis Medicare Services ranks better than 74.25% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Artemis Medicare Services EBITDA Margin % Related Terms
Artemis Medicare Services EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:542919 vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Artemis Medicare Services's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Artemis Medicare Services EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Artemis Medicare Services's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Artemis Medicare Services's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Artemis Medicare Services (BOM:542919) has a EBITDA Margin % of 21.27% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Artemis Medicare Services and its competitors. This is 69% above median its historical median of 12.55. Over the past decade, Artemis Medicare Services' EBITDA Margin % has ranged from 9.24 to 19.88. According to the industry distribution chart, Artemis Medicare Services ranks #171 out of 664 companies in the Healthcare Providers & Services industry, placing it in the top 25.8%.
Is Artemis Medicare Services' EBITDA Margin % too high?
Artemis Medicare Services' current EBITDA Margin % of 21.27% is 69% above median its 10-year median of 12.55. Over the past 10 years, this metric has ranged from a low of 9.24 to a high of 19.88. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Artemis Medicare Services' value of 21.27% is 108.3% above this industry median. Based on the distribution chart, Artemis Medicare Services ranks #171 out of 664 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Artemis Medicare Services has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Artemis Medicare Services' EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Artemis Medicare Services ranks #171 out of 664 companies for EBITDA Margin %. This puts Artemis Medicare Services in the upper half of its industry. The industry median EBITDA Margin % is 10.21. Artemis Medicare Services' value of 21.27% is 108.3% above this benchmark. Historically, Artemis Medicare Services' own EBITDA Margin % has ranged from 9.24 to 19.88 over the past decade. While the company's 10-year median is 12.55 vs. the industry median of 10.21, Artemis Medicare Services has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 664 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Artemis Medicare Services's current EBITDA Margin % of 21.27% is 108.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Artemis Medicare Services and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Artemis Medicare Services's current EBITDA Margin % is 21.27%, which is 69% above median its own 10-year median of 12.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Artemis Medicare Services stock overvalued right now?
Based on GuruFocus' analysis, Artemis Medicare Services (BOM:542919) is currently considered Fairly Valued. The stock's GF Value™ is ₹265.43, compared to a current price of ₹272.40 — trading 2.6% above its estimated fair value. The current EBITDA Margin % is 21.27%, which is 69% above median its 10-year median of 12.55 and 108.3% above the Healthcare Providers & Services industry median of 10.21. Artemis Medicare Services' overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Artemis Medicare Services (BOM:542919), the current EBITDA Margin % is 21.27% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Artemis Medicare Services (BOM:542919) Overvalued in 2026?
Based on GuruFocus' analysis, Artemis Medicare Services stock appears to be overvalued.
The current stock price of ₹272.40 is trading 2.6% above its estimated GF Value™ of ₹265.43.
GuruFocus considers Artemis Medicare Services to be Fairly Valued.
Key valuation signals for BOM:542919:
EBITDA Margin %: 21.27% (69% above median its 10-year median of 12.55)
GF Value™: ₹265.43 vs. price of ₹272.40 (2.6% above fair value)
Industry Position: 108.3% above the Healthcare Providers & Services median (#171 of 664)
No single metric tells the full story. See the BOM:542919 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Artemis Medicare Services Ltd is engaged in managing and operating multi-specialty hospitals. The hospital provides treatments for Allergy and Immunology, Blood (Haematology), Bones, Muscles and Joints (Orthopaedics), Brain, Spine and Nervous System, Cancer (Oncology), Circulatory (Vascular), Digestive (Gastroenterology), Endocrine, Diabetes And Metabolism, Dermatology, Heart (Cardiology), Infectious Diseases, Kidneys (Renal), Lung (Pulmonary), Mouth, Teeth And Face (Oral And Maxillofacial), Obstetrics And Gynecology, Psychiatry, Rheumatology (Arthritis And Joint Disease), Surgery, and Urology. The company derives revenue mainly from Healthcare Services through the operation of multi-specialty Hospitals.
89GF Score
Get the complete analysis for BOM:542919
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:542919 has been successfully added to your 
